Neuroprotection by urate on 6-OHDA-lesioned rat model of Parkinson's disease: Linking to Akt/GSK3β signaling pathway

Journal of Neurochemistry

Volumn 123, Issue 5, 2012, Pages 876-885

  Gong, Li ^a,b   Zhang, Qi Lin ^a   Zhang, Ning ^a,b   Hua, Wen Yan ^a   Huang, Yi Xian ^a   Di, Ping Wei ^a   Huang, Tingting ^a   Xu, Xing Shun ^a,b   Liu, Chun Feng ^a,b   Hu, Li Fang ^a,b   Luo, Wei Feng ^a,b  

^a THE SECOND AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b SOOCHOW UNIVERSITY   (China)

Author keywords

6 OHDA; neuroprotection; oxidative stress; Parkinson's disease; urate

Indexed keywords

GLUTATHIONE; GLYCOGEN SYNTHASE KINASE 3BETA; MALONALDEHYDE; OXIDOPAMINE; PROTEIN KINASE B; SUPEROXIDE DISMUTASE; URATE; URIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME LOCALIZATION; ENZYME METABOLISM; ENZYME PHOSPHORYLATION; IN VITRO STUDY; IN VIVO STUDY; MALE; MOLECULAR DYNAMICS; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RAT; SIGNAL TRANSDUCTION;

ANIMALS; BLOTTING, WESTERN; BRAIN; DOPAMINERGIC NEURONS; GLYCOGEN SYNTHASE KINASE 3; IMMUNOHISTOCHEMISTRY; MALE; NEUROPROTECTIVE AGENTS; PARKINSONIAN DISORDERS; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; URIC ACID;

PARKINSONIA; RATTUS;

EID: 84868654616     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.12038     Document Type: Article

References (28)

1. Annanmaki T., Muuronen A., and, Murros K., (2007) Low plasma uric acid level in Parkinson's disease. Mov. Disord. 22, 1133-1137.
2. Becker B. F., (1993) Towards the physiological function of uric acid. Free Radic. Biol. Med. 14, 615-631.
3. Chang L. W., Chien P. Y., and, Lee C. T., (1999) Measurement of absolute displacement by a double-modulation technique based on a Michelson interferometer. Appl. Opt. 38, 2843-2847.
4. Chen G., Bower K. A., Ma C., Fang S., Thiele C. J., and, Luo J., (2004) Glycogen synthase kinase 3beta (GSK3beta) mediates 6-hydroxydopamine-induced neuronal death. FASEB J. 18, 1162-1164.
5. Chung C. Y., Koprich J. B., Endo S., and, Isacson O., (2007) An endogenous serine/threonine protein phosphatase inhibitor, G-substrate, reduces vulnerability in models of Parkinson's disease. J. Neurosci. 27, 8314-8323.
6. Church W. H., and, Ward V. L., (1994) Uric acid is reduced in the substantia nigra in Parkinson's disease: effect on dopamine oxidation. Brain Res. Bull. 33, 419-425.
7. Cipriani S., Desjardins C. A., Burdett T. C., Xu Y., Xu K., and, Schwarzschild M. A., (2012) Urate and its transgenic depletion modulate neuronal vulnerability in a cellular model of Parkinson's disease. PLoS ONE 7, e37331.
8. Davies K. J., Sevanian A., Muakkassah-Kelly S. F., and, Hochstein P., (1986) Uric acid-iron ion complexes. A new aspect of the antioxidant functions of uric acid. Biochem. J. 235, 747-754.
9. Du Y., Chen C. P., Tseng C. Y., Eisenberg Y., and, Firestein B. L., (2007) Astroglia-mediated effects of uric acid to protect spinal cord neurons from glutamate toxicity. Glia 55, 463-472.
10. Fitzmaurice P. S., Ang L., Guttman M., Rajput A. H., Furukawa Y., and, Kish S. J., (2003) Nigral glutathione deficiency is not specific for idiopathic Parkinson's disease. Mov. Disord. 18, 969-976.
11. Franke T. F., Kaplan D. R., and, Cantley L. C., (1997) PI3K: downstream AKTion blocks apoptosis. Cell 88, 435-437.
12. Guerreiro S., Ponceau A., Toulorge D., Martin E., Alvarez-Fischer D., Hirsch E. C., and, Michel P. P., (2009) Protection of midbrain dopaminergic neurons by the end-product of purine metabolism uric acid: potentiation by low-level depolarization. J. Neurochem. 109, 1118-1128.
13. Hooper D. C., Bagasra O., Marini J. C., et al,. (1997) Prevention of experimental allergic encephalomyelitis by targeting nitric oxide and peroxynitrite: implications for the treatment of multiple sclerosis. Proc. Natl Acad. Sci. USA 94, 2528-2533.
14. Jenner P., and, Olanow C. W., (1998) Understanding cell death in Parkinson's disease. Ann. Neurol. 44, S72-S84.
15. Johnson R. J., Kang D. H., Feig D., Kivlighn S., Kanellis J., Watanabe S., Tuttle K. R., Rodriguez-lturbe B., Herrera-Acosta J., and, Mazzali M., (2003) Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 41, 1183-1190.
16. Kikuchi Y., Yasuhara T., Agari T., et al,. (2011) Urinary 8-OHdG elevations in a partial lesion rat model of Parkinson's disease correlate with behavioral symptoms and nigrostriatal dopaminergic depletion. J. Cell. Physiol. 226, 1390-1398.
17. Kutzing M. K., and, Firestein B. L., (2008) Altered uric acid levels and disease states. J. Pharmacol. Exp. Ther. 324, 1-7.
18. de Lau L. M., Koudstaal P. J., Hofman A., and, Breteler M. M., (2005) Serum uric acid levels and the risk of Parkinson disease. Ann. Neurol. 58, 797-800.
19. Maesaka J. K., Wolf-Klein G., Piccione J. M., and, Ma C. M., (1993) Hypouricemia, abnormal renal tubular urate transport, and plasma natriuretic factor(s) in patients with Alzheimer's disease. J. Am. Geriatr. Soc. 41, 501-506.
20. Mizuno Y., Yoshino H., Ikebe S., Hattori N., Kobayashi T., Shimoda-Matsubayashi S., Matsumine H., and, Kondo T., (1998) Mitochondrial dysfunction in Parkinson's disease. Ann. Neurol. 44, S99-S109.
21. Patterson R. A., Horsley E. T., and, Leake D. S., (2003) Prooxidant and antioxidant properties of human serum ultrafiltrates toward LDL: important role of uric acid. J. Lipid Res. 44, 512-521.
22. Schwarzschild M. A., Schwid S. R., Marek K., et al,. (2008) Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch. Neurol. 65, 716-723.
23. Scott G. S., Spitsin S. V., Kean R. B., Mikheeva T., Koprowski H., and, Hooper D. C., (2002) Therapeutic intervention in experimental allergic encephalomyelitis by administration of uric acid precursors. Proc. Natl Acad. Sci. USA 99, 16303-16308.
24. Scott G. S., Cuzzocrea S., Genovese T., Koprowski H., and, Hooper D. C., (2005) Uric acid protects against secondary damage after spinal cord injury. Proc. Natl Acad. Sci. USA 102, 3483-3488.
25. Simola N., Morelli M., and, Carta A. R., (2007) The 6-hydroxydopamine model of Parkinson's disease. Neurotox. Res. 11, 151-167.
26. Wang L. J., Luo W. F., Wang H. H., Ni G. H., Ye Y., Li D., and, Liu C. F., (2010) Protective effects of uric acid on nigrostriatal system injury induced by 6-hydroxydopamine in rats. Zhonghua Yi Xue Za Zhi 90, 1362-1365.
27. Weisskopf M. G., O'Reilly E., Chen H., Schwarzschild M. A., and, Ascherio A., (2007) Plasma urate and risk of Parkinson's disease. Am. J. Epidemiol. 166, 561-567.
28. Zhu T. G., Wang X. X., Luo W. F., Zhang Q. L., Huang T. T., Xu X. S., and, Liu C. F., (2012) Protective effects of urate against 6-OHDA-induced cell injury in PC12 cells through antioxidant action. Neurosci. Lett. 506, 175-179.